Chris O’Dell, SVP of market solutions at Turquoise Health, discusses why it's important to a shine a light on this aspect of the healthcare ecosystem.
Mike Hollan
Advertisement
Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.
Articles by Mike Hollan
Chris O’Dell, SVP of market solutions at Turquoise Health, explains the timeline to expect changes to prescription drug prices based on current DTC trend.
Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.
Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.
The proposed change would add a warning about an increased risk of autism, despite a lack of scientific evidence connecting the medication to the condition.
The company will hold an Extraordinary General Meeting in November to elect new members.
Jesse Mendelsohn, executive vice president at Model N, explains the pros and cons of continuing to pursue DTC programs once the government-run program launches.
Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.
The two companies are the latest to join the DTC offerings to address high drug prices.
Nine medications are on the initial list of program participants.
The President claimed that prices would drop significantly based on government negotiations.
Jesse Mendelsohn, executive vice president at Model N, discusses how selling drugs directly to patients differs from traditional government programs.
As timelines change, medical affairs teams must adjust their skillsets.
Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.
Efforts to regulate pharma prices will impact other sectors of healthcare, with PBMs likely to feel the impact.
The current administration’s efforts are just the latest attempt from the government to improve drug prices in the US.
The company’s CEO will reportedly joining the President to announce the deal.
Multiple pharma companies have already announced plans to invest in domestic projects.
As drug prices in the US fluctuate, pharma companies may look to other regions for opportunity.
Pharma companies have the choice of facing strict tariffs or negotiating with the current administration.
Gen Li, founder and president of Phesi, discusses how the industry is considering GLP-1s from a more holistic approach.
Products tested and manufactured exclusively from domestic materials will be eligible for the program.
Kitamura discusses implementing cost management initiatives and positioning the company to weather near-term challenges.
Gen Li, founder and president of Phesi, discusses how the rise of GLP-1 medications is impacting how various diseases are treated beyond the ones the medications are specifically designed to treat.
This marks the latest change in the President’s strategy.
Details of the agreement are confidential, but it reportedly fulfills the requirements President Trump set forth in a July 31st letter to the company.
The MFN executive order may result in the US losing its place as the friendliest market for innovation.
The move will allow stocks to be traded across the US, London, and Stockholm exchanges.
The news comes just days after President Trump’s announcement on 100%-pharma tariffs.
The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a post-pandemic world.
Advertisement